Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques.

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61

Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98

Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73

Sexual transmission of HIV. N Engl J Med (1997) 6.84

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14

Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol (2005) 5.76

Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med (2008) 5.14

The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol (2006) 4.26

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06

Antibody-antigen complexes. Annu Rev Biochem (1990) 3.91

Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol (2003) 3.64

Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol (2007) 3.61

Intrinsic and extrinsic factors in protein antigenic structure. Science (1985) 3.54

Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol (1994) 2.95

Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol (1997) 2.60

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature (2015) 2.56

HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A (2001) 2.54

Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A (2006) 2.54

Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS (2001) 2.28

Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance. N Engl J Med (1987) 2.18

A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol (2002) 1.97

Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol (2003) 1.80

Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol (1999) 1.65

Epitope mapping: the first step in developing epitope-based vaccines. BioDrugs (2007) 1.58

Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol (2003) 1.53

Structural features of the reactions between antibodies and protein antigens. FASEB J (1995) 1.36

Infection with "escaped" virus variants impairs control of simian immunodeficiency virus SIVmac239 replication in Mamu-B*08-positive macaques. J Virol (2009) 1.33

Intestinal double-positive CD4+CD8+ T cells are highly activated memory cells with an increased capacity to produce cytokines. Eur J Immunol (2006) 1.31

The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters. J Acquir Immune Defic Syndr (2004) 1.31

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis (2005) 1.23

Control of simian immunodeficiency virus SIVmac239 is not predicted by inheritance of Mamu-B*17-containing haplotypes. J Virol (2006) 1.22

IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses (2010) 1.18

Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3). Virology (2007) 1.14

Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol (2001) 1.08

Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge. Virology (2009) 1.01

Double-positive CD21+CD27+ B cells are highly proliferating memory cells and their distribution differs in mucosal and peripheral tissues. PLoS One (2011) 0.97

Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. Blood (2011) 0.95

Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother (2003) 0.95

Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread. J Exp Med (2006) 0.95

Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol (2010) 0.92

Simian immunodeficiency virus infection in rhesus macaques induces selective tissue specific B cell defects in double positive CD21+CD27+ memory B cells. Clin Immunol (2011) 0.91

Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients. Clin Diagn Lab Immunol (1996) 0.87

Effects of alcohol consumption on antigen-specific cellular and humoral immune responses to SIV in rhesus macaques. J Acquir Immune Defic Syndr (2013) 0.87

HIV-specific antibodies but not t-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J Acquir Immune Defic Syndr (2006) 0.86

Molecular characterization of the HIV-1 gag nucleocapsid gene associated with vertical transmission. Retrovirology (2006) 0.83

Human monoclonal antibodies to HIV-1: cross-reactions with gag and env products. Clin Exp Immunol (1989) 0.83

Lack of interleukin-10-mediated anti-inflammatory signals and upregulated interferon gamma production are linked to increased intestinal epithelial cell apoptosis in pathogenic simian immunodeficiency virus infection. J Virol (2014) 0.82

Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users. J Biol Regul Homeost Agents (1992) 0.80

Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine. DNA Cell Biol (2002) 0.77